Talis Biomedical (NASDAQ:TLIS) Stock Price Down 1.7% – What’s Next?

Talis Biomedical Co. (NASDAQ:TLIS) shares fell 1.7% during mid-day trading on Tuesday . The stock traded as low as $1.77 and last traded at $1.77. 139 shares changed hands during trading, a decline of 99% from the average session volume of 13,211 shares. The stock had previously closed at $1.80.

Talis Biomedical Stock Down 1.7 %

The company has a market cap of $3.22 million, a PE ratio of -0.06 and a beta of 1.58. The stock’s 50 day simple moving average is $1.77 and its two-hundred day simple moving average is $4.96.

Hedge Funds Weigh In On Talis Biomedical

An institutional investor recently raised its position in Talis Biomedical stock. BML Capital Management LLC grew its holdings in Talis Biomedical Co. (NASDAQ:TLIS) by 481.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 248,702 shares of the company’s stock after acquiring an additional 205,959 shares during the period. Talis Biomedical comprises approximately 0.3% of BML Capital Management LLC’s holdings, making the stock its 24th biggest holding. BML Capital Management LLC owned about 13.66% of Talis Biomedical worth $460,000 as of its most recent SEC filing. 43.77% of the stock is currently owned by institutional investors.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.